Inovio Pharmaceuticals Inc INO

• Type of Vaccine: DNA plasmid vaccine
• Stage of Development: Preclinical

Applied DNA Sciences Inc APDN & Takis Biotech

• Type of Vaccine: Linear DNA vaccine
• Stage of Development: Preclinical

Johnson & Johnson’s JNJ 0.11% Janssen Unit

• Type of Vaccine: non-replicating viral vector
• Stage of Development: Preclinical

Altimmune Inc ALT

• Type of Vaccine: non-replicating viral vector
• Stage of Development: Preclinical

Novavax, Inc. NVAX

• Type of Vaccine: nanoparticle vaccine
• Stage of Development: Preclinical

Moderna Inc MRNA

• Type of Vaccine: mRNA
• Stage of Development: Preclinica

Vaxart Inc VXRT

• Type of Vaccine: oral vaccine
• Stage of Development: Preclinical

BioNTech SE – ADR BNTX

• Type of Vaccine: mRNA
• Stage of Development: Preclinical

Other Companies, Institutions Working On Coronavirus

• GlaxoSmithKline plc GSK 0.01% and the Chinese biotech Clover Biopharma: Clover’s protein based vaccine candidate S-Trimer is to be tested with Glaxo’s pandemic adjuvant system (preclinical testing).
• Sanofi SA SNY: working with BARDA to develop a COVID-19 vaccine using its recombinant DNA platform (preclinical testing).
• Tonix Pharmaceuticals Holding Corp TNXP with Southern Research: TNX-1800, a modified version of its Tonix’s horsepox virus vaccine for subcutaneous administration (preclinical testing).
• Geovax Labs Inc GOVX and Wuhan, China-based BravoVax: GeoVax is using its GV-MVA-VLP vaccine platform to design and construct vaccine candidates using genetic sequences from COVID-19 virus (preclinical testing).
• Arcturus Therapeutics Ltd ARCT: The company is working with the Duke-NUS Medical School in Singapore to develop a vaccine candidate using its proprietary Self-Transcribing and Replicating RNA technology (preclinical testing).
• University of Oxford: The university is working with Italian manufacturer Advent Srl to produce the first batch of a vaccine candidate codenamed ChAdOx1 nCoV-19 for clinical testing (preclinical testing).
• CureVac: The company said March 3 it is selecting the most suitable mRNA vaccine candidates from several constructs and it is also coordinating with the German Paul Ehrlich Institute for accelerated clinical development of these candidate. The company expects to start clinical trials in early summer.